• Dovitinib: RTK Assays That Translate

  2026-08-19

  Build sharper RTK-driven cancer experiments with Dovitinib (TKI-258, CHIR-258), from pathway suppression and apoptosis readouts to model-specific optimization. This guide distinguishes biochemical potency from cellular response and shows how immune-signature methods can strengthen translational assay design without overstating the evidence.

• Recombinant Human Oncostatin M: Assay Workflows

  2026-08-18

  Build reproducible proliferation and cytokine-release assays with a tag-free, low-endotoxin OSM preparation. This guide connects practical rh-Oncostatin M workflows with differentiation-focused experimental design while clearly separating established product performance from exploratory applications.

• Proteoform-Specific Drug Interactions in Native Membranes

  2026-08-18

  This Nature Chemistry study introduces native top-down mass spectrometry for defining how membrane-protein proteoforms, lipid modifications, and drug interactions are connected in an intact cellular membrane environment. Using retinal rhodopsin, G proteins, and PDE6, it shows why ligand selectivity and off-target binding can depend on proteoform identity rather than protein name alone.

• 4-Phenylbutyric Acid as an ER Stress Probe

  2026-08-17

  4-Phenylbutyric acid (4-PBA) is more than a chemical chaperone: it can function as a causal perturbation tool for connecting ER stress with autophagic cell death. This guide explains how to interpret 4-PBA rescue experiments, select orthogonal readouts, and apply the approach to liver cancer models.

• Sulfo-Cy5 NHS Ester in Translational Immunology

  2026-08-17

  Mechanistic immuno-oncology increasingly depends on spatially resolved evidence, not pathway diagrams alone. This article explains how Sulfo-Cy5 NHS ester and Sulfo-Cyanine5 Succinimidyl Ester can support aqueous biomolecule labeling, dendritic-cell uptake studies, and translational assays inspired by recent work on metal-ion-chelating phenylalanine nanostructures.

• Pseudo-UTP for Modified mRNA Synthesis

  2026-08-16

  Pseudo-UTP is a Pseudo-modified uridine triphosphate used as a UTP substitute for RNA synthesis by in vitro transcription. Pseudouridine-containing RNA can show improved stability, translation, and reduced innate immune recognition in defined experimental systems, but product performance remains dependent on template, polymerase, purification, formulation, and delivery.

• MRSA Research: From Evolution to Clinical Care

  2026-08-15

  Turner and colleagues integrate molecular, epidemiological, transmission, surveillance, and clinical evidence to explain why methicillin-resistant Staphylococcus aureus remains a globally important pathogen despite regional declines. The review’s central contribution is its linked view of MRSA as a genetically diverse organism that moves between colonization, community and healthcare transmission, and invasive disease, with treatment success dependent on both antimicrobial selection and source control.

• Streptavidin-Cy3 Workflows for NPC Metastasis

  2026-08-15

  Translate biotinylated RNA and protein targets into bright, spatially resolved readouts for nasopharyngeal carcinoma research. This guide connects Streptavidin-Cy3 with ISH, IHC, immunofluorescence, and flow cytometry while emphasizing controls, quantitative imaging, and troubleshooting.

• SU6656 Src tyrosine kinases inhibitor Workflow

  2026-08-14

  Use SU6656 as a controlled Src-signaling perturbation in hiPSC-derived megakaryocyte studies, while preserving a separate, preclinical path for endothelial radiosensitization. This workflow connects dose handling, polyploidization assays, platelet function testing, and radiation-response controls without confusing exploratory conditions with validated protocol components.

• Oligomycin A in TAM Metabolic Assays

  2026-08-14

  Oligomycin A is a mitochondrial ATP synthase inhibitor that converts tumor-associated macrophage metabolism into a testable bioenergetic phenotype. This article explains how to use it alongside the 25-hydroxycholesterol–AMPK–STAT6 axis while distinguishing functional mitochondrial stress from pathway-specific mechanism.

• ω-Agatoxin IVA TFA for Cav2.1 Assays

  2026-08-13

  Use ω-Agatoxin IVA TFA to isolate Cav2.1-dependent calcium entry, presynaptic release, and PV-interneuron circuit maturation with greater subtype precision than broad calcium-channel blockers. This guide connects neuronal calcium current recording to synaptic transmission research, epilepsy animal model design, and neuroprotection while emphasizing controls, dosing logic, and troubleshooting.

• Nilotinib Beyond BCR-ABL: Assay Logic for Repurposing

  2026-08-13

  Nilotinib and AMN-107 are best known for selective BCR-ABL inhibition, but their value in translational research depends on how kinase, protein-processing, and mitochondrial assays are interpreted together. This guide uses recent Alzheimer’s disease evidence to define practical assay decisions without overstating repurposing claims.

• IGF2BP1–TUBB4B Signaling in Liver Fibrosis

  2026-08-12

  The reference study identifies an m6A-dependent IGF2BP1–TUBB4B–FAK axis that promotes hepatic stellate cell activation, proliferation, and migration. Its combination of transcriptomic re-analysis, RNA-binding evidence, genetic perturbation, and pharmacological testing provides a framework for studying RNA-stability mechanisms in liver fibrosis.

• High-Throughput MoA Discovery in M. tuberculosis

  2026-08-12

  Santa Maria et al. developed a machine-learning framework that connects phenotypic antibacterial activity with biophysical target binding and chemical structure. By integrating historical screens with ALIS profiling, the study recovered known mechanisms and prospectively identified nanomolar Mycobacterium tuberculosis dihydrofolate reductase inhibitors, demonstrating a practical route from screening data to mechanism-of-action hypotheses.

• Atorvastatin as a Ferroptosis Research Tool

  2026-08-11

  Atorvastatin is more than an HMG-CoA reductase inhibitor: it is a pathway-level probe linking mevalonate biology to ferroptosis in hepatocellular carcinoma. This guide translates recent evidence into practical assay design, controls, and cross-domain interpretation for cardiovascular and oncology research.

459 records 8/31 page Previous Next First page 上5页 678910 下5页 Last page